TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06349122

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal flora abnormalities screening and quantification using molecular biology technique
Description: Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycine
Description: In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
Study: NCT06205576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB catheter
Description: Trade name of DCB catheter：Acoart Orchid＆Dhalia
Study: NCT06454071

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
Study: NCT06073444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus JP
Description: Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
Study: NCT06107907

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)
Description: Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)
Description: Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
Study: NCT05798013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health management
Description: The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.
Study: NCT06138002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumbaCure®
Description: LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercises supervised by the physiotherapist
Description: A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
Study: NCT05540041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bubble breathing play therapy group
Description: The efficacy of bubble breathing play therapy in the preoperative anxiety children and their parent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tell-show-do play therapy group
Description: The efficacy of tell-show-do play therapy in the preoperative anxiety children and their parent.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Routine nursing care
Study: NCT05427318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PATH
Description: The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
Study: NCT06649188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate Iontophoresis
Description: Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED) The phoresors II auto model PM850 IOMED allows the user to deliver a specific dose from 0 to 80 mA/min, control the current from 0 to 4 mA and automatically calculates required time for the selected dose. Current ramp-up and down, shut-off, error messages and safety checks are also performed automatically. The builtin option for manual current shut-off is an added safety feature (Teslim et al., 2013).~* Electrodes: Active-Anode (Drug Delivery).~* Drug Used: MgSO4 Aqueous Solution.~* Drug Ion Polarity: Positive Polarity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: Deep friction massage, stretching and pressure therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional physical therapy program
Description: Deep friction massage, stretching and pressure therapy.
Study: NCT06648109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Blanket
Description: Participants were randomized to groups A and B. When the subject\&#39;s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
Study: NCT06649461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozone injections
Description: Ozone injections (5 mL/10 μg/dL) were administered under aseptic conditions, with the wrist fixed in dorsiflexion, and with the insulin injector, a 23-gauge needle was inserted between the palmaris longus and flexor carpi radialis muscles at a 45-degree angle from the palmar distal line (Salutem/19147884379).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: hand splint for night

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: hand splint for night
Study: NCT06373458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 50mg QD for 36 weeks starting at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 50mg QD for 36 weeks starting at Day 1
Study: NCT05725265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large-area low-level laser therapy(Venusure)
Description: The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional low-level laser therapy
Description: The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
Study: NCT04714788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECAP_MyLife mobile app
Description: The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual data collection methods
Description: Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
Study: NCT05469763

Intervention type: OTHER
Group type: OTHER
Intervention: Circuit training
Description: Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training
Description: Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week.
Study: NCT04699201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hincisional hernia prevention by onlay prosthesis trocar closure
Description: Hincisional hernia prevention by onlay prosthesis trocar closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with or without common bile duct exploration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with or without common bile duct exploration
Study: NCT06293014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102+bevacizumab
Description: TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy+bevacizumab
Description: Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
Study: NCT04699201

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal ultrasound
Description: Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Description: Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
Study: NCT05739799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL
Description: Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode
Description: patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
Study: NCT05307237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continous Glucose Monitoring Management
Description: CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care - Blinded Continuous Glucose Monitoring Management
Description: CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
Study: NCT06219681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active neurofeedback
Description: The session will be done on an individual basis. The active group will receive neurofeedback training from the repetitive negative thinking (RNT) related brain functional connectivity.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
Study: NCT04530877

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition
Description: the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
Study: NCT06337240

Intervention type: OTHER
Intervention: Pelvic floor on COPD patients
Description: Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months.

Intervention type: OTHER
Intervention: Pilates exercises on COPD patients
Description: Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months.
Study: NCT06262776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine adjuvanted (SHINGRIX)
Description: 2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
Study: NCT05207631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic and standardised assessment of inhalers and implementation of a prescribing guide
Description: Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
Study: NCT06344364

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Description: Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Description: Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
Study: NCT06330233

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Moxibustion
Description: The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control.~The conventional treatment group received mecobalamin tablets and epastat orally for four weeks along with their daily treatment.~Moxibustion 15 minutes group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.~Moxibustion 15 minutes group of Part Two will use the same intervention as above.~Moxibustion 30 minutes group: Except for the operating time others are the same as the Moxibustion 15 minutes group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control.~The conventional treatment group received mecobalamin tablets and epastat orally for four weeks along with their daily treatment.~Moxibustion 15 minutes group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.~Moxibustion 15 minutes group of Part Two will use the same intervention as above.~Moxibustion 30 minutes group: Except for the operating time others are the same as the Moxibustion 15 minutes group.
Study: NCT05387681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: short course radiotherapy ：5\*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
Study: NCT06330233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control.~The conventional treatment group received mecobalamin tablets and epastat orally for four weeks along with their daily treatment.~Moxibustion 15 minutes group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.~Moxibustion 15 minutes group of Part Two will use the same intervention as above.~Moxibustion 30 minutes group: Except for the operating time others are the same as the Moxibustion 15 minutes group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control.~The conventional treatment group received mecobalamin tablets and epastat orally for four weeks along with their daily treatment.~Moxibustion 15 minutes group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.~Moxibustion 15 minutes group of Part Two will use the same intervention as above.~Moxibustion 30 minutes group: Except for the operating time others are the same as the Moxibustion 15 minutes group.
Study: NCT05041842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Initial loading: 840 mg Maintenance: 420 mg, 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Description: Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab/ Trastuzumab
Description: Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly
Study: NCT06350591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: single-leg immobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Leg extension and leg press; 3 sets of 8-12 reps